Tilray Brands, Inc. (TLRY)
Pre-market:
| Previous close | 2.1200 |
| Open | 2.0650 |
| Bid | 1.9600 x 11400 |
| Ask | 1.9900 x 3300 |
| Day's range | 1.9500 - 2.0800 |
| 52-week range | 1.5000 - 3.4000 |
| Volume | |
| Avg. volume | 35,629,201 |
| Market cap | 1.622B |
| Beta (5Y monthly) | 2.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.36 |
- Yahoo Finance Video
Tilray preps for marijuana reclassification, may sell stock
Shares of Tilray Brands (TLRY) fell sharply on Friday after filing to offer up to $250 million worth of additional shares. The company says the funds would be used to make acquisitions or other investments, not for general purposes. Tilray says it is positioning itself to be ready for the potential reclassification of marijuana, something President Biden voiced support for on Thursday. Yahoo Finance's Julie Hyman and Josh Lipton recap the latest developments for Tilray. This post was written by Stephanie Mikulich.
GlobeNewswireTilray Brands Announces At-The-Market Program to Fund Strategic and Accretive Acquisitions and Accelerate Expansion Plan Upon U.S. Cannabis Rescheduling When Effective
NEW YORK and LEAMINGTON, Ontario, May 17, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY), a leading global lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell shares of its common stock (“Common Stock”) having an aggregate
ReutersCannabis stocks rally after DOJ proposal to reclassify marijuana
Cannabis stocks including Tilray, Curaleaf, and the AdvisorShares Pure US Cannabis ETF rallied on Thursday after the U.S. Department of Justice unveiled a historic proposal to ease restrictions on marijuana. Under the proposal, cannabis would be reclassified from a so-called Schedule I drug, which are considered highly additive with no medical benefits, to a Schedule III, signifying it has moderate to low potential for physical and psychological dependence. "No safety concerns were identified in the FDA's review that would indicate that medical use of marijuana poses unacceptably high safety risks," the proposal says.
